低剂量未修饰mRNA狂犬病疫苗(脂质纳米颗粒)人体首次试验
在比利时和德国开展的一期多中心对照试验中,55名健康成人接种CV7202(mRNA-LNP)或对照狂犬病疫苗。5μg剂量反应原性过高,1μg和2μg两剂后全部受试者中和抗体达WHO标准,且57天GMT与对照疫苗无显著差异。
要点
- 5μg CV7202反应原性过高不可接受,1μg和2μg耐受性更好。
- 两剂1μg或2μg后第43天全部受试者VNT≥0.5 IU/mL。
- CV7202诱导的VNT与RABV-G特异性IgG显著相关(r²=0.8319,p<0.0001)。
核心结论
- 两剂1μg或2μg CV7202耐受良好,全部受试者狂犬病中和抗体应答达WHO标准。
- 5μg剂量作为预防性疫苗反应原性不可接受。
研究设计与样本
- 一期多中心对照试验,在比利时和德国入组55名18-40岁健康成人。
- 受试者第1天肌注5μg(n=10)、1μg(n=16)或2μg(n=16)CV7202;1μg和2μg组各8人第29天接种第二剂。
- 对照组10人第1、8、29天接种Rabipur狂犬病疫苗。
主要发现
- 第29天,1μg、2μg和5μg组分别有31%、22%和31%受试者VNT≥0.5 IU/mL。
- 两剂1μg或2μg后第43天全部受试者抗体滴度≥0.5 IU/mL。
- 第57天GMT与Rabipur组无显著差异,Rabipur两剂后全部受试者应答充分。
- CV7202诱导的VNT与RABV-G特异性IgG显著相关(r²=0.8319,p<0.0001)。
- 未发生疫苗相关严重不良事件或退出。
关键数值与推荐
- WHO标准:VNT≥0.5 IU/mL视为充分应答。
- 1μg和2μg组第29天VNT≥0.5 IU/mL比例分别为31%和22%,5μg组为31%。
- 两剂1μg或2μg后第43天全部受试者VNT≥0.5 IU/mL。
临床怎么用
- 低剂量1μg或2μg CV7202两剂方案可诱导符合WHO标准的狂犬病中和抗体应答。
- 5μg剂量因反应原性过高不适用于预防性疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In a first-in-human study immune responses to rabies virus glycoprotein (RABV-G)-mRNA vaccine were dependent on the route of administration, necessitating specialized devices. Following successful preclinical studies with mRNA encapsulated in lipid nanoparticles (LNP), we tested an mRNA-LNP formulation (CV7202). METHODS: In this phase 1, multi-center, controlled study in Belgium and Germany we enrolled 55 healthy 18-40-year-olds to receive intramuscular injections of 5 μg (n = 10), 1 μg (n = 16), or 2 μg (n = 16) CV7202 on Day 1; subsets (n = 8) of 1 μg and 2 μg groups received second doses on Day 29. Controls (n = 10) received rabies vaccine, Rabipur, on Days 1, 8 and 29. Safety and reactogenicity were assessed up to 28 days post-vaccination using diary cards; immunogenicity was measured as RABV-G-specific neutralizing titers (VNT) by RFFIT and IgG by ELISA. RESULTS: As initially tested doses of 5 μg CV7202 elicited unacceptably high reactogenicity we subsequently tested 1 and 2 μg doses which were better tolerated. No vaccine-related serious adverse events or withdrawals occurred. Low, dose-dependent VNT responses were detectable from Day 15 and by Day 29%, 31% and 22% of 1, 2 and 5 μg groups, respectively, had VNTs ≥ 0·5 IU/mL, considered an adequate response by the WHO. After two 1 or 2 μg doses all recipients had titers ≥ 0.5 IU/mL by Day 43. Day 57 GMTs were not significantly lower than those with Rabipur, which elicited adequate responses in all vaccinees after two doses. CV7202-elicited VNT were significantly correlated with RABV-G-specific IgG antibodies (r2 = 0.8319, p < 0.0001). CONCLUSIONS: Two 1 μg or 2 μg doses of CV7202 were well tolerated and elicited rabies neutralizing antibody responses that met WHO criteria in all recipients, but 5 μg had unacceptable reactogenicity for a prophylactic vaccine. ClinicalTrials.gov Identifier: NCT03713086.
引用
- Aldrich C, Leroux-Roels I, Huang KB, et al. Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial. Vaccine. 2021. PMID: 33487468. doi:10.1016/j.vaccine.2020.12.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。